

Food and Drug Administration  
Rockville MD 20857

#30

RECEIVED

APR 08 2003

OFFICE OF PETITIONS

Re: Tequin  
Docket No.: 01E-0030

The Honorable James E. Rogan  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 2327  
Arlington, VA 22202

FEB 24 2003

~~FEB 21 2002~~

FEB 24 2003

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 4,980,470, filed by Kyorin Pharmaceutical Company through Bristol Myers Squibb, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Tequin, the human drug product claimed by the patent.

The total length of the regulatory review period for Tequin is 1,087 days. Of this time, 732 days occurred during the testing phase and 355 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: December 27, 1996.

The applicant claims December 26, 1996, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was December 27, 1996, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: December 28, 1998.

FDA has verified the applicant's claim that the new drug application (NDA) for Tequin (NDA 21-061) was initially submitted on December 28, 1998.


3. The date the application was approved: December 17, 1999.

FDA has verified the applicant's claim that NDA 21-061 was approved on December 17, 1999.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: David M. Mase  
Bristol Myers Squibb  
Patent Counsel-Wallingford  
5 Research Parkway  
Wallingford, CT 06492